Perrigo Plc (PRGO) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Perrigo Company Plc  (NYSE: PRGO)

Select the Financial Report: Select the Period:


Description of Perrigo Plc's Business Segments


Perrigo Company Plc is a prominent global healthcare organization that operates through three primary segments: Consumer Healthcare, Branded Consumer Healthcare, and Prescription Pharmaceuticals. Each segment targets distinct market needs while providing a diverse array of products and services that cater to various consumer and healthcare professional demands.

Consumer Healthcare Segment

The Consumer Healthcare Segment is primarily devoted to over-the-counter (OTC) products, which consumers can purchase without a prescription. This segment addresses an extensive range of health and wellness needs, focusing on convenience and accessibility for consumers.

Key product categories within this segment include:

1. Allergy and Cold Remedies: Products designed to alleviate symptoms associated with allergies and the common cold, including antihistamines, decongestants, and cough syrups.

2. Digestive Health Products: A range of laxatives, fiber supplements, antacids, and probiotics aimed at enhancing digestive function and relieving gastrointestinal discomfort.

3. Wound Care Treatments: This includes antiseptic solutions, dressings, and topical ointments aimed at promoting healing of minor cuts and burns.

4. Pain Relief Products: Over-the-counter pain management options, including analgesics like acetaminophen and ibuprofen that are used for temporary relief of pain and fever.

5. Oral Care Products: A variety of solutions for dental health, including toothpaste, mouth rinses, and whitening products.

The Consumer Healthcare segment serves markets in North America, Europe, and Australia, offering well-known brands such as GoodSense, MiraLAX, Rogaine, and Luvena—all designed to address everyday health concerns with effective and trusted formulations.

Branded Consumer Healthcare Segment

The Branded Consumer Healthcare Segment emphasizes brand recognition and targeted solutions for specific health conditions. This segment operates primarily in North America and Europe, providing products designed to meet distinct consumer needs and preferences.

Product offerings include:

1. Skincare Products: A portfolio of treatments for various skin conditions, including moisturizers, acne solutions, and anti-aging creams. Brands such as Clear Eyes offer specialized products for eye care, blending skincare principles with ocular health.

2. Sleep Aids: Solutions formulated to assist those struggling with sleep issues, including OTC sleep medications and natural sleep aids promoting restful sleep.

3. Women’s Health Products: A range of items addressing specific health concerns for women, such as menstrual relief, prenatal vitamins, and products targeting menopause symptoms.

4. Smoking Cessation Aids: Products designed to help users quit smoking, including nicotine replacement therapies and support materials that guide individuals through the cessation process.

Prominent brands within this segment include Wintergreen and Germolene, addressing a variety of consumer health requirements with a focus on efficacy and brand loyalty.

Prescription Pharmaceuticals Segment

The Prescription Pharmaceuticals Segment is pivotal to Perrigo’s commitment to treating various health conditions through both branded and generic prescription medications. This segment possesses a footprint that spans global markets including the Americas, Europe, and Asia Pacific.

Key areas of focus include:

1. Dermatology Products: A diverse range of topical treatments for skin conditions, including prescription creams and ointments that address eczema, psoriasis, and other dermatological disorders.

2. Oncology Products: This includes chemotherapeutic agents and supportive care medications designed for the treatment of cancer across various types and stages.

3. Ophthalmic Products: Prescription solutions for eye health, addressing conditions such as glaucoma, dry eye syndrome, and infections.

The segment also offers a portfolio of generic prescription products, which includes established brands like Fucidin (for dermatological infections), Nitrofurantoin (for urinary tract infections), and Tadalafil (for erectile dysfunction).

Additional Services

Beyond these primary segments, Perrigo extends its capabilities through various services tailored to support pharmaceutical companies and healthcare providers. These include:

- Contract Manufacturing Services: Offering expertise in the production of OTC and prescription products, enabling clients to harness Perrigo’s manufacturing and quality assurance capabilities for their product lines.

- Research and Development: A robust R&D framework allows Perrigo to innovate and develop new formulations, actively contributing to the advancement of healthcare solutions.

- Regulatory Affairs: Expertise in navigating the complex regulatory landscape ensures that products meet the necessary standards for safety and efficacy, providing support from product conception through to market entry.

Conclusion

Perrigo Company Plc stands as a comprehensive healthcare provider, blending a wide-ranging product portfolio with significant service offerings that enhance their ability to meet diverse consumer demands and support the healthcare industry effectively. By addressing a multitude of health concerns through accessible and effective solutions, Perrigo continues to fulfill its commitment to improving the health and well-being of individuals globally.


Composition of Perrigo Company Plc Revenues by Segments

 
Self Care    56.1 % of total Revenue
Specialty Care    21.37 % of total Revenue
Infant Formula    9.26 % of total Revenue
Upper Respiratory Self Care    20.38 % of total Revenue
Digestive Health Self Care    9.97 % of total Revenue
Healthy Lifestyle Self Care    14.73 % of total Revenue
Pain Sleep Self Care    11.01 % of total Revenue
Skin Health Specialty Care    15.68 % of total Revenue
Women s Health Specialty Care    5.69 % of total Revenue
U S    57.24 % of total Revenue
Europe    40.41 % of total Revenue
All other countries    2.42 % of total Revenue
Ireland    0.42 % of total Revenue
All Other    13.34 % of total Revenue

Q1 three months ended (Mar 28 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Self Care 543.30 56.1 %
Specialty Care 207.00 21.37 %
Infant Formula 89.70 9.26 %
Upper Respiratory Self Care 197.40 20.38 %
Digestive Health Self Care 96.60 9.97 %
Healthy Lifestyle Self Care 142.70 14.73 %
Pain Sleep Self Care 106.60 11.01 %
Skin Health Specialty Care 151.90 15.68 %
Women s Health Specialty Care 55.10 5.69 %
U S 554.40 57.24 %
Europe 391.40 40.41 %
All other countries 23.40 2.42 %
Ireland 4.10 0.42 %
All Other 129.20 13.34 %
Total 968.50 100 %




Q1 three months ended (Mar 28 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Self Care -11.56 % -
Specialty Care 3.97 % -
Infant Formula 2.16 % -
Upper Respiratory Self Care -8.06 % -
Digestive Health Self Care -14.44 % -
Healthy Lifestyle Self Care -9.11 % -
Pain Sleep Self Care -17.81 % -
Skin Health Specialty Care 1.54 % -
Women s Health Specialty Care 11.31 % -
U S -9.01 % -
Europe -5.07 % -
All other countries 4.93 % -
Ireland -62.73 % -
All Other -9.46 % -
Total -7.17 % -77.23 %




Q1 three months ended (Mar 28 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -398.60 -




Q1 three months ended (Mar 28 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Perrigo Company Plc Divisions, Sales by Country

 
Europe   Europe Segment contribution to total sales 38.01 % of total Revenue
Ireland   Ireland Segment contribution to total sales 0.99 % of total Revenue
CSCA   CSCA Segment contribution to total sales 60.79 % of total Revenue
CSCA Upper Respiratory   CSCA Upper Respiratory Segment contribution to total sales 12.45 % of total Revenue
CSCA Nutrition   CSCA Nutrition Segment contribution to total sales 9.61 % of total Revenue
CSCA Digestive Health   CSCA Digestive Health Segment contribution to total sales 10.4 % of total Revenue
CSCA Pain and Sleep-Aids   CSCA Pain and Sleep-Aids Segment contribution to total sales 7.82 % of total Revenue
CSCA Healthy Lifestyle   CSCA Healthy Lifestyle Segment contribution to total sales 7.44 % of total Revenue
CSCA Oral Care   CSCA Oral Care Segment contribution to total sales 6.04 % of total Revenue
CSCA Skin Care   CSCA Skin Care Segment contribution to total sales 5.05 % of total Revenue
CSCA Women s Health   CSCA Women s Health Segment contribution to total sales 1.7 % of total Revenue
CSCA Vitamins Minerals and Supplements VMS   CSCA Vitamins Minerals and Supplements VMS Segment contribution to total sales 0.17 % of total Revenue
CSCI   CSCI Segment contribution to total sales 39.22 % of total Revenue
CSCI Upper Respiratory   CSCI Upper Respiratory Segment contribution to total sales 6.78 % of total Revenue
CSCI Digestive Health   CSCI Digestive Health Segment contribution to total sales 0.95 % of total Revenue
CSCI Pain and Sleep-Aids   CSCI Pain and Sleep-Aids Segment contribution to total sales 5.54 % of total Revenue
CSCI Healthy Lifestyle   CSCI Healthy Lifestyle Segment contribution to total sales 5.44 % of total Revenue
CSCI Oral Care   CSCI Oral Care Segment contribution to total sales 2.29 % of total Revenue
CSCI Skin Care   CSCI Skin Care Segment contribution to total sales 9.59 % of total Revenue
CSCI Women s Health   CSCI Women s Health Segment contribution to total sales 3.37 % of total Revenue
CSCI Vitamins Minerals and Supplements VMS   CSCI Vitamins Minerals and Supplements VMS Segment contribution to total sales 3.79 % of total Revenue
United States   United States Segment contribution to total sales 59.73 % of total Revenue
All Other Countries   All Other Countries Segment contribution to total sales 2.27 % of total Revenue
CSCA Other CSCA   CSCA Other CSCA Segment contribution to total sales 0.11 % of total Revenue
CSCI Other CSCI   CSCI Other CSCI Segment contribution to total sales 1.47 % of total Revenue
Contract Manufacturing   Contract Manufacturing Segment contribution to total sales 6.37 % of total Revenue


Twelve months ended 2025
PRGO s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Europe 1,616.30 38.01 %
Ireland 42.10 0.99 %
Total 4,252.50 100 %
CSCA 2,585.30 60.79 %
CSCA Upper Respiratory 529.50 12.45 %
CSCA Nutrition 408.50 9.61 %
CSCA Digestive Health 442.10 10.4 %
CSCA Pain and Sleep-Aids 332.50 7.82 %
CSCA Healthy Lifestyle 316.40 7.44 %
CSCA Oral Care 256.90 6.04 %
CSCA Skin Care 214.90 5.05 %
CSCA Women s Health 72.40 1.7 %
CSCA Vitamins Minerals and Supplements VMS 7.20 0.17 %
CSCI 1,667.70 39.22 %
CSCI Upper Respiratory 288.20 6.78 %
CSCI Digestive Health 40.30 0.95 %
CSCI Pain and Sleep-Aids 235.40 5.54 %
CSCI Healthy Lifestyle 231.50 5.44 %
CSCI Oral Care 97.50 2.29 %
CSCI Skin Care 407.70 9.59 %
CSCI Women s Health 143.50 3.37 %
CSCI Vitamins Minerals and Supplements VMS 161.20 3.79 %
United States 2,540.10 59.73 %
All Other Countries 96.70 2.27 %
CSCA Other CSCA 4.80 0.11 %
CSCI Other CSCI 62.40 1.47 %
Contract Manufacturing 270.90 6.37 %


Twelve months ended 2025
PRGO s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -1,425.40 -
CSCA 754.90 29.2 %
CSCI 739.70 44.35 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
U S - -
Europe 0.73 % -
Ireland 6.31 % -
Total -2.75 % -
CSCA -4.02 % -3.11 %
CSCA Upper Respiratory 5.84 % -
CSCA Nutrition -9.12 % -
CSCA Digestive Health -11.12 % -
CSCA Pain and Sleep-Aids -3.76 % -
CSCA Healthy Lifestyle 3.13 % -
CSCA Oral Care -6.72 % -
CSCA Skin Care -2.36 % -
CSCA Women s Health -10.73 % -
CSCA Vitamins Minerals and Supplements VMS -50.34 % -
CSCI -0.71 % -3.12 %
CSCI Upper Respiratory 2.16 % -
CSCI Digestive Health 10.41 % -
CSCI Pain and Sleep-Aids 5.94 % -
CSCI Healthy Lifestyle 2.52 % -
CSCI Oral Care -1.91 % -
CSCI Skin Care -0.56 % -
CSCI Women s Health 8.06 % -
CSCI Vitamins Minerals and Supplements VMS -7.09 % -
United States -4.12 % -
All Other Countries -19.08 % -
CSCA Other CSCA 54.84 % -
CSCI Other CSCI -35.87 % -
Contract Manufacturing -11.53 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.